Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 2/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18748440 | 0.87 | GAA (0.60) | ACKR3MEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL18748439 | 0.86 | MEN1 (0.55) | MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL17372463 | 0.80 | KDM4E (0.66) | MEN1KMT2ATMEM97SIGMAR1HDAC1 | |
| SCHEMBL17117270 | 0.79 | MEN1 (0.64) | ACKR3MEN1KMT2ATMEM97SIGMAR1 | |
| SCHEMBL17372569 | 0.78 | TMEM97 (0.58) | MEN1KMT2ATMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL40675 | 0.77 | KDM4A (0.66) | KMT2ATMEM97SIGMAR1KDM4AKDM4C | |
| SCHEMBL17372411 | 0.77 | SIGMAR1 (0.62) | MEN1KMT2ATMEM97SIGMAR1HDAC1 | |
| SCHEMBL17372619 | 0.76 | TMEM97 (0.63) | MEN1KMT2ATMEM97SIGMAR1HDAC1 | |
| SCHEMBL39945 | 0.76 | KDM4E (0.56) | ACKR3TMEM97SIGMAR1APPACHE | |
| SCHEMBL17372516 | 0.75 | TMEM97 (0.60) | TMEM97SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE (FR) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | ACKR3 4070/4885MEN1 2161/4885KMT2A 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.